Form 4: Sutro Biopharma Executive Linda Fitzpatrick Reports Stock Option and RSU Grants, Share Disposals

Linda Fitzpatrick, Chief People & Communications Officer of Sutro Biopharma, reports the acquisition of stock options and restricted stock units (RSUs), as well as the disposal of shares to cover tax obligations.

Summary

• On March 5, 2024, Linda Fitzpatrick, Chief People & Communications Officer of Sutro Biopharma, engaged in transactions involving the company's stock.
• Fitzpatrick acquired 38,000 stock options with an exercise price of $4.54, vesting monthly from April 1, 2024, and expiring on March 5, 2034.
• She also acquired 28,500 RSUs vesting annually from March 1, 2025, and expiring on March 1, 2028.
• Additionally, 8,750 RSUs were settled, resulting in the acquisition of 8,750 shares.
• To cover income tax withholding obligations, 3,108 shares were withheld by the issuer at a price of $4.54 per share.
• On March 7, 2024, Fitzpatrick acquired 22,000 stock options with an exercise price of $4.8, vesting monthly from April 1, 2024, and expiring on March 7, 2034.
• She also acquired 16,500 RSUs vesting annually from March 1, 2025, and expiring on March 1, 2028.
• Following these transactions, Fitzpatrick directly owns 72,952 shares and indirectly owns 10,383 shares through a family trust.

Sentiment

Score: 6

Explanation: The document reflects standard executive compensation practices, with a neutral sentiment. The grants are positive for incentivizing the executive, but the share disposal is a minor negative.

Positives

• The grant of stock options and RSUs to a key executive aligns her interests with those of the shareholders.
• The vesting schedules of the options and RSUs incentivize continued service to the company.

Negatives

• The disposal of shares to cover tax obligations, while common, slightly reduces the executive's direct stake in the company.

Risks

• Executive compensation packages, including stock options and RSUs, can be subject to scrutiny if not aligned with company performance.
• Changes in tax laws could impact the attractiveness of equity-based compensation.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the stock options and RSUs.

Industry Context

Equity-based compensation is a common practice in the biopharmaceutical industry to attract and retain talent, aligning executive interests with shareholder value.

Comparison to Industry Standards

• Stock option and RSU grants are standard components of executive compensation packages in the biotechnology industry.
• Vesting schedules are typically structured to incentivize long-term performance and retention, similar to practices at companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals.
• Tax withholding practices related to RSU settlements are also common across the industry.

Stakeholder Impact

• Shareholders may view the equity grants as a positive incentive for the executive.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates